Reduction of free fatty acids, safety, and pharmacokinetics of oral GS-9667, an a1 adenosine receptor partial agonist

Journal of Clinical Pharmacology

Volumn 53, Issue 4, 2013, Pages 385-392

  Staehr, Peter M ^a   Dhalla, Arvinder K ^a   Zack, Julia ^a   Wang, Xuegong ^a   Ho, Yu L ^a   Bingham, Justus ^a   Belardinelli, Luiz ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

A1 adenosine receptor partial agonist; Anti lipolytic; FFA

Indexed keywords

ADENOSINE RECEPTOR STIMULATING AGENT; GS 9667; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; BRADYCARDIA; CONSTIPATION; CONTACT DERMATITIS; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; DYSLIPIDEMIA; ECG ABNORMALITY; FATTY ACID BLOOD LEVEL; FEMALE; FLUSHING; GASTRITIS; HEADACHE; HERPES SIMPLEX; HUMAN; HUMAN EXPERIMENT; HYPOTENSION; INJECTION SITE PAIN; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MIGRAINE; MUSCLE STRAIN; MUSCULOSKELETAL PAIN; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL HUMAN; OTALGIA; PHARMACOKINETICS; PHARYNGITIS; PLASMA CONCENTRATION-TIME CURVE; PR PROLONGATION; RHINORRHEA; SIDE EFFECT; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ADENOSINE; ADENOSINE A1 RECEPTOR AGONISTS; ADOLESCENT; ADULT; FATTY ACIDS, NONESTERIFIED; FEMALE; HUMANS; MALE; MIDDLE AGED; OBESITY; YOUNG ADULT;

EID: 84877864904     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.9     Document Type: Article

References (15)

1. Reaven GM. The insulin resistance syndrome: definition and dietary approaches to treatment. Ann Rev Nutr. 2005;25:391-406.
2. Boden G. Free fatty acids-the link between obesity and insulin resistance. Endocr Pract. 2001;7:44-51.
3. Doyle ME, Egan JM. Pharmacological agents that directly modulate insulin secretion. Pharm Rev. 2003;55:105-131.
4. Schernthaner G, Chilton RJ. Cardiovascular risk and thiazolidinediones- what do meta-analyses really tell us? Diabetes Obes Metab. 2010;12:1023-1035.
5. Bristol-Myers Squibb Company. Glucophage, (Metformin Hydrochloride) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company. http://packageinserts.bms.com/pi/pi-glucophage. pdf. Accessed 8 February, 2011.
6. Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab. 2004;89:463-478.
7. Delarue J, Magnan C. Free fatty acids and insulin resistance. Curr Opin Clin Nutr Metab Care. 2007;10:142-148.
8. Santomauro AT, Boden G, Silva ME, et al. Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects. Diabetes. 1999;48:1836-1841.
9. Bajaj M, Suraamornkul S, Romanelli A, et al. Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients. Diabetes. 2005;54:3148-3153.
10. Karpe F, Frayn KN. The nicotinic acid receptor-A new mechanism for an old drug. Lancet. 2004;363:1892-1894.
11. Grundy SM, Vega GL, McGovern ME, et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of Niaspan trial. Arch Intern Med. 2002;162:1568-1576.
12. Dhalla A, Chisholm JW, Reaven GM, Belardinelli L. A1 Adenosine receptor: role in diabetes and obesity. In: Wilson CN, Mustafa SJ, eds. Adenosine Receptors in Health and Disease. Handbook Exp Pharmacol, Vol. 193. Berlin, Heidelberg: Springer-Verlag; 2009: 271-295.
13. Fatholahi M, Xiang Y, Wu Y, et al. A novel partial agonist of the A1-adenosine receptor and evidence of receptor homogeneity in adipocytes. J Pharmacol Exp Ther. 2006;317: 676-684
14. Dhalla A, Santikul M, Smith M, Wong MY, Shryock J, Belardinelli L. Antilipolytic activity of a novel partial A1 adenosine receptor agonist devoid of cardiovascular effects: comparison with nicotinic acid. J Pharmacol Exp Ther. 2007;321:327-333.
15. Elzein E, Zablocki J. A1 adenosine receptor agonists and their potential therapeutic applications. Expert Opin Investig Drugs. 2008;17:1901-1910.